Top Markets
#1 Cysic Cysic +7.96%
#2 Palladium Network Palladium Network +6.82%
#3 Pieverse Pieverse +3.88%
#4 Akedo Akedo +2.15%
#5 Bless Bless +1.27%
#6 aPriori aPriori +1.17%
#7 Prom Prom +1.16%
#8 Zest Protocol Zest Protocol +1.01%
#9 Test Test +0.95%
#10 Open Campus Open Campus +0.84%
Coin of the day
Cysic Cysic
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Clasificación en acciones #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Precio por acción
$0.01292666
Última sincronización: 2025-04-08
Capitalización bursátil
$157.54K
Cambio (1 día)
6.84%
Cambio (1 año)
0.00%
País
GB
Comercio Synairgen plc (SNG)

Categoría

Healthcare
Ratio P/S de Synairgen plc (SNG)
Ratio P/S al August 2026 TTM: 0.00
Según los informes financieros más recientes y el precio de las acciones de Synairgen plc, el ratio P/S actual (TTM) es 0.00. Al final de 2022, el ratio P/S era 0.00.
Historial del ratio P/S de Synairgen plc desde 2004 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 86.19K 5,474.43%
2017 1.55K 0.00%
2016 0.00 -100.00%
2015 589.54K 12,229.42%
2014 4.78K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 68.65 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 134.85 -99.56%
2006 30.85K 158.87%
2005 11.92K 8,695.11%
2004 135.48 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE